Cancer Cell International, 2021 Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini +6 more
doaj +1 more source
A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]
, 2016 Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis +10 more
core +1 more source
Breast, 2021 Background: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of ...
I-Chun Chen +6 more
doaj +1 more source
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]
, 2016 Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan +21 more
core +2 more sources
Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis [PDF]
, 2016 Background: Radiotherapy has a central role in the treatment of sinonasal malignancies, either as postoperative or as primary therapy. To study the efficacy and safety of intensity modulated radiotherapy (IMRT) for sinonasal tumors a single center ...
Askoxylakis, Vasileios +6 more
core +1 more source
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]
, 2017 Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A +82 more
core +1 more source
Экструдируемые гетеромодульные полимер-полимерные композиты на основе сверхвысокомолекулярной матрицы [PDF]
, 2005 Purpose:The aim of the present study was to define gene expression profiles of noninvasive and invasive bladder cancer, to identify potential therapeutic or screening targets in bladder cancer, and to define genetic changes relevant for tumor progression
Hartmann, Arndt +9 more
core +1 more source
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]
, 2013 IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P +19 more
core +2 more sources
Chromothripsis and progression-free survival in metastatic colorectal cancer
Molecular and Clinical Oncology, 2017 Metastatic dissemination of the primary tumor is the major cause of death in colorectal cancer (CRC) patients. Multiple chromosomal breaks and chromothripsis, a phenomenon involving multiple chromosomal fragmentations occurring in a single catastrophic event, are associated with cancer genesis, progression and developing of metastases.
Edvins Miklasevics +6 more
openaire +3 more sources
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma [PDF]
, 2018 Background: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs.
Deptala, A +11 more
core +3 more sources